Galderma targets Ozempic face with new treatment testing

Galderma, Natura and L'Oreal are testing treatments for "Ozempic face," targeting consumers concerned about facial changes after weight loss.

The Swiss skincare company, Brazilian cosmetics group and beauty company are pursuing demand associated with obesity medicines. Their focus is on consumers seeking help with sagging skin and reduced facial fullness, rather than treatments for obesity itself.

Weight loss creates a treatment opening

The expression "Ozempic face" emerged as Ozempic, a diabetes medicine made by Novo Nordisk, became associated with weight reduction. Experts cited in the report attribute the facial changes to losing weight rapidly, not to GLP-1 medicines themselves.

That distinction separates the consumer label from the underlying concern. The commercial opportunity described for beauty companies involves changes following weight loss, rather than a condition established as specific to one branded medicine.

GLP-1 medicines mimic a hormone that promotes a feeling of fullness. Products in this category include Novo Nordisk's Ozempic and Wegovy, alongside Eli Lilly's Zepbound.

Gastrointestinal effects are among the side effects associated with these medicines. Rapid weight reduction can also leave skin loose elsewhere on the body, extending the concern beyond the face.

Pfizer's forecast frames the opportunity

Pfizer estimates that annual obesity-medicine sales could reach $150 billion by 2030. That figure is a projection for the drug market, not an estimate of spending on skincare or aesthetic procedures.

The distinction matters when assessing the opportunity for Galderma, Natura and L'Oreal. A forecast for medicine sales does not establish how many patients will seek cosmetic treatment, what they will spend or how much revenue the beauty companies might generate.

The companies' testing puts the response at a development stage rather than demonstrating a proven commercial result. No treatment-specific efficacy findings, prices or launch schedules are identified, leaving the scale and timing of any business opportunity unresolved.

Testing leaves commercial returns unsettled

If obesity-drug use expands and more patients seek help with post-weight-loss skin changes, the three companies could gain another source of demand. For the wider skincare and medical-aesthetics sector, the mechanism would be spending on an additional need arising after weight reduction, rather than spending on the medicines themselves.

If those concerns do not translate into purchases, growth in obesity medicines would not necessarily deliver comparable gains for beauty businesses. The central commercial uncertainty is the conversion of consumer concern into demand for treatments with demonstrated benefits.

The broader economic implications are also conditional. If consumers add aesthetic treatments to their purchases, that would represent additional demand; if they redirect existing beauty budgets, the effect would instead be a change in the composition of spending.

For Galderma, Natura and L'Oreal, evidence from testing is the next substantive measure of progress. Demonstrated results and eventual commercial terms would help distinguish a viable treatment business from an opportunity inferred from the expansion of obesity medicines.